Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jun;98(24):e16026.
doi: 10.1097/MD.0000000000016026.

Comparison of the efficacy and safety of phloroglucinol and magnesium sulfate in the treatment of threatened abortion: A meta-analysis of randomized controlled trials

Shaofei Yuan  1 , Fengli Gao  1 , Zhong Xin  1 , Haijun Guo  1 , Suqin Shi  1 , Lei Shi  2 , Xia Yang  3 , Jingzhi Guan  4
Affiliations
Free PMC article
Meta-Analysis

Comparison of the efficacy and safety of phloroglucinol and magnesium sulfate in the treatment of threatened abortion: A meta-analysis of randomized controlled trials

Shaofei Yuan et al. Medicine (Baltimore). 2019 Jun.
Free PMC article

Abstract

Background: To compare the clinical efficacy and safety of phloroglucinol (PHL) and magnesium sulfate (MS) in the treatment of threatened abortion through systematic review.

Methods: Foreign databases, such as the Cochrane Library, PubMed and EMBASE, and Chinese databases, including the China Biology Medicine disc (SinoMed), China National Knowledge Infrastructure (CNKI), Chongqing VIP (VIP) and WanFang Data, were searched. Published randomized controlled trials (RCTs) documents obtained from these databases were included if they were associated with the research objective. The search timeframe was from the beginning of the establishment of each database to May 2018. Document selection, data abstraction and document quality evaluation were independently performed by 2 investigators. A combined analysis of the data was performed for those documents that fulfilled the study requirements; Rev Man 5.3 and Stata 12.0 software were used to compare and analyze the 2 drugs in terms of the total effective rate (TER), rate of adverse events, time required to relieve uterine contractions, onset time, time of complete relief of uterine contraction symptoms, medication duration and length of hospital stay.

Results: A total of 21 RCT trials were included in the present research, according to the inclusion criteria. However, the quality of the included studies was low. The meta-analysis suggested that the TER and drug onset time of PHL were higher than those for MS, while the rate of adverse events, the time required to relieve uterine contractions, time to complete relief of uterine contraction symptoms, drug continuous treatment time and length of hospital stay were shorter than those for MS.

Conclusion: The clinical efficacy of PHL is better than that of MS, and PHL obviously results in fewer adverse reactions than MS. However, due to poor quality of evidence, high quality, multi-center RCTs with large samples are required for further verification.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The document selection flowchart.
Figure 2
Figure 2
Risk of bias.
Figure 3
Figure 3
Risk of bias summary.
Figure 4
Figure 4
A forest map of the meta-analysis of the TER of phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 5
Figure 5
A sensitivity map of the TER of phloroglucinol versus magnesium sulfate in the treatment of threatened abortion.
Figure 6
Figure 6
The results of the meta-analysis of the incidence rate of flush and redness associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 7
Figure 7
The results of the meta-analysis of the incidence rate of dizziness and headache associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 8
Figure 8
The results of the meta-analysis of the incidence rate of gastrointestinal discomfort associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 9
Figure 9
The results of the meta-analysis of the incidence rate of palpitation associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 10
Figure 10
The result of the meta-analysis about the incidence rate of nausea and vomiting associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 11
Figure 11
The results of the meta-analysis of the incidence rate of dry mouth associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 12
Figure 12
The results of the meta-analysis of the incidence rate of perspiration associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 13
Figure 13
The results of the meta-analysis of the incidence rate of insomnia associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 14
Figure 14
The results of the meta-analysis of the incidence rate of a lack of strength association with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 15
Figure 15
The results of the meta-analysis of the incidence of chest tightness associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 16
Figure 16
The results of the meta-analysis of the time required to relieve uterine contractions associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 17
Figure 17
The sensitivity analysis results for the time required to relieve uterine contractions associated with phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 18
Figure 18
The meta-analysis results for the drug onset time of phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 19
Figure 19
The results of the meta-analysis of the complete relief of uterine contraction symptoms after phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 20
Figure 20
The sensitivity analysis of the results of the complete relief of uterine contraction symptoms after phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 21
Figure 21
The results of the meta-analysis of the drug continuous treatment time of phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 22
Figure 22
The results of the meta-analysis of the length of hospital stay after phloroglucinol vs magnesium sulfate in the treatment of threatened abortion.
Figure 23
Figure 23
The TER of phloroglucinol vs magnesium sulfate, according to Egger test, in the treatment of threatened abortion.
Figure 24
Figure 24
The time required to relieve uterine contractions associated with phloroglucinol versus magnesium sulfate, according to Egger test, in the treatment of threatened abortion.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhang Y. The progress of Chinese and Western medicine treatment for threatened abortion. Beijing J Tradit Chin Med 2009;28:566–9.
    1. Petriglia G, Palaia I, Musella A, et al. Threatened abortion and late-pregnancy complications: a case-control study and review of literature. Minerva Ginecol 2015;67:491–7. - PubMed
    1. Kryvopustov OS, Dosenko VE. Pogesterone receptor gene polymorphisms as genetic risk factor of threatened abortion. Fiziol Zh 2016;62:60–4. - PubMed
    1. Lee HJ, Park TC, Kim JH, et al. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. Biomed Res Int 2017;2017:3616875doi: 10.1155/2017/3616875. - PMC - PubMed
    1. Pabuccu R, Akar ME. Luteal phase support in assisted reproductive technology. Curr Opin Obstet Gynecol 2005;17:277. - PubMed

MeSH terms